Cargando…

The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy

Immune checkpoint blockade has recently proven effective in subsets of patients with esophageal adenocarcinoma (EAC) but little is known regarding the EAC immune microenvironment. We determined the single cell transcriptional profile of EAC in 8 patients who were treatment-naive (n = 4) or had recei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Croft, Wayne, Evans, Richard P. T., Pearce, Hayden, Elshafie, Mona, Griffiths, Ewen A., Moss, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575245/ https://www.ncbi.nlm.nih.gov/pubmed/36253784 http://dx.doi.org/10.1186/s12943-022-01666-x

Ejemplares similares

Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
por: Izadi, Fereshteh, et al.
Publicado: (2021)

Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
por: Arbore, Giuseppina, et al.
Publicado: (2023)

The transcriptional landscape of endogenous retroelements delineates esophageal adenocarcinoma subtypes
por: Kazachenka, Anastasiya, et al.
Publicado: (2023)

Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2021)

The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation
por: Humphries, Matthew P., et al.
Publicado: (2020)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers
por: To, Natalie, et al.
Publicado: (2022)

Predictive value of immuno-inflammatory and nutritional measures modulated by neoadjuvant chemotherapy on the response of neoadjuvant chemotherapy and long-term outcomes in patients with esophageal cancer
por: Ishibashi, Yusuke, et al.
Publicado: (2020)

Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma
por: Obulkasim, Askar, et al.
Publicado: (2016)

Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma
por: Borg, David, et al.
Publicado: (2018)

Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis
por: Chidambaram, Swathikan, et al.
Publicado: (2022)

Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma
por: Velandia, Carlos, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma
por: Brunner, Robert, et al.
Publicado: (2019)

Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
por: Seo, Dongjin, et al.
Publicado: (2023)

FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal–gastric junction
por: Fencl, Pavel, et al.
Publicado: (2016)

Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma
por: Wen, Jing, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series
por: Hadzitheodorou, Christina, et al.
Publicado: (2017)

Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes
por: Abdo, Joe, et al.
Publicado: (2017)

Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
por: Matani, Hirsch, et al.
Publicado: (2022)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Does chemotherapy regimen matter in the neoadjuvant treatment of esophageal cancer?
por: Logarajah, Shankar, et al.
Publicado: (2022)

A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas
por: Adams, Olivia, et al.
Publicado: (2018)

Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma
por: Petrillo, A., et al.
Publicado: (2022)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience
por: Yu, Bin, et al.
Publicado: (2015)

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
por: Li, Keting, et al.
Publicado: (2023)

Retraction: Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes
por: Frontiers Editorial Office,
Publicado: (2019)

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrett’s carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy
por: Fassan, Matteo, et al.
Publicado: (2016)

Correction: A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas
por: Adams, Olivia, et al.
Publicado: (2019)

High Infiltration of CD68(+)/CD163(−) Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma
por: Svensson, Maria C., et al.
Publicado: (2022)

Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics
por: Yang, Yushang, et al.
Publicado: (2023)

Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta‐analysis
por: Fan, Mengying, et al.
Publicado: (2015)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Effects of neoadjuvant chemotherapy combined with radiotherapy in patients with advanced esophageal carcinoma
por: Liu, Yu, et al.
Publicado: (2017)

Efficacy of immunonutritional supplement after neoadjuvant chemotherapy in patients with esophageal cancer
por: Luo, Chao, et al.
Publicado: (2022)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy
por: Aichler, Michaela, et al.
Publicado: (2014)

Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response
por: Kotsafti, Andromachi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fvuo7offfv6fsnl1gdlo2up67e